<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363531">
  <stage>Registered</stage>
  <submitdate>18/01/2013</submitdate>
  <approvaldate>24/01/2013</approvaldate>
  <actrnumber>ACTRN12613000096752</actrnumber>
  <trial_identification>
    <studytitle>A study on the effectiveness of Indomethacin in preventing post Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis</studytitle>
    <scientifictitle>Among patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP), does a single dose of Indomethacin reduce the incidence of Post-ERCP Pancreatitis?</scientifictitle>
    <utrn>U1111-1138-6774</utrn>
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Indomethacin is a Non-Steroidal Anti-inflammatory Drug (NSAID), which is commonly used to treat fever, headaches, and bone, muscular or joint pain. It works by inhibiting the production of prostaglandins (known to cause such symptoms). It is marketed under several names, including Indocid and Arthrexin.
In our study, participants will be given an Indomethacin suppository (dose given rectally) 5 minutes before the commencement of the ERCP.
We will then be monitoring our patients for 90 minutes post procedure for symptoms, which would suggest pancreatitis (in particular abdominal pain).
</interventions>
    <comparator>Currently there are no wide accepted methods used for the prevention of post-ERCP pancreatitis.
The control group will be using a placebo suppository (glucose).</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome will be Post-ERCP Pancreatitis, which is defined as:
-new-onset abdominal pain
-elevation of serum amylase (greater than 3 times the upper limit of normal) after 24 hours
-requiring more than 2 days hospitalization</outcome>
      <timepoint>Patients will be observed for 90 minutes post-procedure and then reassessed at the 24 hour mark</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Acute renal impairment (via serum creatinine measurement 24 hours post procedure)</outcome>
      <timepoint>24 hours post procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients undergoing Endoscopic Retrograde Cholangiopancreatography</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-Those with active pancreatitis
-Renal impairment
-known allergy to non-steroidal anti-inflammatory drugs (including NSAID induced asthma)
-patients with concomitant NSAID therapy (excluding Aspirin)
-patients without a native papilla
-Active peptic ulcer disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>20/02/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>The Queen Elizabeth Hospital - Woodville</hospital>
    <hospital>Lyell McEwin Hospital - Elizabeth Vale</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5011 - Woodville</postcode>
    <postcode>5112 - Elizabeth Vale</postcode>
    <postcode>5042 - Bedford Park</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Vinh-An Phan</primarysponsorname>
    <primarysponsoraddress>Department of Gastroenterology and Hepatology
Ward Q7
Royal Adelaide Hospital
North Terrace
Adelaide CBD
South Australia 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Department of Gastroenterology and Hepatology</fundingname>
      <fundingaddress>Ward Q7
Royal Adelaide Hospital
Adelaide
South Australia 5000
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Mark Schoeman</sponsorname>
      <sponsoraddress>Department of Gastroenterology and Hepatology
Ward Q7
Royal Adelaide Hospital
North Terrace
Adelaide CBD
South Australia 5000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We propose a randomised control study to assess the use of prophylactic Non-steroidal Anti-inflammatory Drugs for the prevention of Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Research Ethics Committee</ethicname>
      <ethicaddress>Level 3 Hanson Institute
IMVS Building
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>25/01/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Vinh-An Phan</name>
      <address>Department of Gastroenterology and Hepatology
Ward Q7
Royal Adelaide Hospital
North Terrace
Adelaide CBD
SA 5000
</address>
      <phone>+61 08 82224000</phone>
      <fax />
      <email>vinhan.phan@gmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Vinh-An Phan</name>
      <address>Department of Gastroenterology and Hepatology
Ward Q7
Royal Adelaide Hospital
North Terrace
Adelaide CBD
SA 5000</address>
      <phone>+61 08 82224000</phone>
      <fax />
      <email>vinhan.phan@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Vinh-An Phan</name>
      <address>Department of Gastroenterology and Hepatology
Ward Q7
Royal Adelaide Hospital
North Terrace
Adelaide CBD
SA 5000</address>
      <phone>+61 08 82224000</phone>
      <fax />
      <email>vinhan.phan@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>